Sirolimus vs paclitaxel for femoropopliteal peripheral artery disease - The limus flow randomized trial

29 August 2025 (09:15 - 10:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Christos Rammos

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

4 More presentations in this session

Presentation thumbnail

Pathology of balloon angioplasty for below the knee arteries in patients with chronic limb threatening ischemia

Doctor M. Shiozaki (Kanagawa, JP)

Abstract Slides Video

Presentation thumbnail

The predictors of clinical outcome in the patients undergoing endovascular intervention for lower extremity peripheral arterial disease

Professor B. Kim (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

Clinical impact of endovascular therapy with paclitaxel-based strategy for femoropopliteal lesions in chronic limb-threatening ischaemia

Mr H. Nohara (Sakai, JP)

Abstract Slides Video

Presentation thumbnail

Long-term prognosis after bypass surgery versus endovascular therapy in chronic hemodialysis patients with peripheral artery disease -10-year follow-up study

Doctor Y. Kumada (Kasamatsu, JP)

Abstract Slides Video

Access the full session

Session thumbnail

Peripheral angioplasty and complications

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET

You may be interested in

Congress Presentation

Treatment of coronary artery disease with sirolimus- versus paclitaxel-coated balloons

Congress Presentation

Biolimus-coated balloon or sirolimus-coated balloon vs paclitaxel-coated balloon for in-stent restenosis: a systematic review and meta-analysis

Congress Presentation

Biolimus A9 DEB for the Treatment of In-Stent Restenosis. 1-year outcomes of the REFORM trial.

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources